Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphomas
Abramson Cancer Center at Penn Medicine
Summary
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age \> 18 years * Subject must be able and willing to provide informed consent. In the case where the patient is incapacitated or not otherwise capable, a legally authorized representative (or decision maker when there is not an advanced directive in place) must be willing to provide informed consent on behalf of the patient. * Able to comply with the study protocol, in the investigator's judgment * ECOG PS of 0 - 2 * Pathology report confirming eligible diagnosis * Documented CD20+ tumor cells on most recent biopsy * Patients will have failed to respond to frontline sta…
Interventions
- DrugEpcoritamab
* C1D1: fixed priming dose of 0.16 mg subcutaneous injection * C1D8: fixed intermediate dose of 0.8 mg subcutaneous injection * C1D15 onward: fixed full dose of 48 mg subcutaneous injection
Location
- Abramson Cancer Center at the University of PennsylvaniaPhiladelphia, Pennsylvania